Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secukinumab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT05734482
What this trial is testing

Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers

Who this might be right for
Psoriasis
Taizhou Mabtech Pharmaceutical Co.,Ltd 130
Post-approval studies (Phase 4)Study completedNCT04080661
What this trial is testing

Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.

Who this might be right for
Psoriasis Vulgaris
University Hospital, Ghent 82
Large-scale testing (Phase 3)Study completedNCT02394561
What this trial is testing

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)

Who this might be right for
Plaque Type Psorisis
Novartis Pharmaceuticals 434
Not applicableStudy completedNCT02786186
What this trial is testing

A Registry of Patients With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Novartis Pharmaceuticals 2,376
Early research (Phase 1)Study completedNCT03342573
What this trial is testing

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

Who this might be right for
PITYRIASIS RUBRA PILARIS
Mayo Clinic 12
Large-scale testing (Phase 3)Study completedNCT02721966
What this trial is testing

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement

Who this might be right for
Axial Psoratic Arthritis
Novartis Pharmaceuticals 503
Large-scale testing (Phase 3)Study completedNCT02159053
What this trial is testing

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

Who this might be right for
Spondylitis, Ankylosing
Novartis Pharmaceuticals 350
Post-approval studies (Phase 4)Study completedNCT04717466
What this trial is testing

Brain Changes in Psoriasis After Secukinumab Treatment

Who this might be right for
PsoriasisHealthy
University of Miami 20
Not applicableNot Yet RecruitingNCT07690319
What this trial is testing

Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

Who this might be right for
Hidradenitis Suppurativa
Novartis Pharmaceuticals 186
Large-scale testing (Phase 3)Study completedNCT03713619
What this trial is testing

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

Who this might be right for
Hidradenitis Suppurativa
Novartis Pharmaceuticals 544
Large-scale testing (Phase 3)Ended earlyNCT04237116
What this trial is testing

Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)

Who this might be right for
Plaque PsoriasisNon-alcoholic Fatty Liver Disease
Novartis Pharmaceuticals 10
Post-approval studies (Phase 4)Not Yet RecruitingNCT06833112
What this trial is testing

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

Who this might be right for
Ankylosing Spondylitis
The Affiliated Hospital Of Guizhou Medical University 10
Post-approval studies (Phase 4)Not Yet RecruitingNCT07704190
What this trial is testing

Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease

Who this might be right for
Cardiorenal Metabolic SyndromeAtherosclerotic Cardiovascular DiseaseChronic Kidney Disease+5 more
Peking University Third Hospital 100
Large-scale testing (Phase 3)Ended earlyNCT05758415
What this trial is testing

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Who this might be right for
Rotator Cuff Tendinopathy
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT01359943
What this trial is testing

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

Who this might be right for
Rheumatoid Arthritis
Novartis Pharmaceuticals 221
Post-approval studies (Phase 4)Study completedNCT02592018
What this trial is testing

Immunologic Response to Secukinumab in Plaque Psoriasis

Who this might be right for
Psoriasis
University of California, San Francisco 15
Large-scale testing (Phase 3)Study completedNCT05767034
What this trial is testing

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Who this might be right for
Polymyalgia Rheumatica
Novartis Pharmaceuticals 381
Testing effectiveness (Phase 2)Study completedNCT01250171
What this trial is testing

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Who this might be right for
Dry Eye
Novartis Pharmaceuticals 72
Large-scale testing (Phase 3)Study completedNCT04179175
What this trial is testing

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Who this might be right for
Hidradenitis Suppurativa
Novartis Pharmaceuticals 702
Testing effectiveness (Phase 2)Study completedNCT01537432
What this trial is testing

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Who this might be right for
Psoriasis, Plaque-type Psoriasis
Novartis Pharmaceuticals 36
Next Page